TCS-OX2-29: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== TCS-OX2-29 == | |||
[[File:TCS-OX2-29.svg|thumb|right|Chemical structure of TCS-OX2-29]] | |||
TCS-OX2-29 | '''TCS-OX2-29''' is a selective antagonist of the [[orexin receptor]] OX2, which is involved in the regulation of [[wakefulness]] and [[sleep]]. Orexin receptors are a type of [[G protein-coupled receptor]] that bind the [[neuropeptide]]s [[orexin A]] and [[orexin B]]. These receptors play a crucial role in maintaining [[arousal]], [[appetite]], and [[energy homeostasis]]. | ||
== | == Mechanism of Action == | ||
TCS-OX2-29 | TCS-OX2-29 functions by selectively inhibiting the OX2 receptor, thereby blocking the action of orexin peptides at this receptor site. This inhibition can lead to a decrease in [[arousal]] and an increase in [[sleep]], making it a potential therapeutic agent for conditions such as [[insomnia]] and [[narcolepsy]]. | ||
== | == Pharmacological Effects == | ||
TCS-OX2-29 is | The primary effect of TCS-OX2-29 is the modulation of sleep-wake cycles. By antagonizing the OX2 receptor, TCS-OX2-29 can promote sleep and reduce wakefulness. This effect is particularly useful in studying the role of orexin in sleep disorders and in developing treatments for such conditions. | ||
== | == Research and Development == | ||
Research on TCS-OX2-29 has focused on its potential applications in treating sleep disorders. Studies have shown that blocking the OX2 receptor can lead to increased sleep duration and improved sleep quality. This makes TCS-OX2-29 a valuable tool in both basic research and clinical applications. | |||
== | == Related Pages == | ||
* [[Orexin receptor]] | * [[Orexin receptor]] | ||
* [[Orexin]] | * [[Orexin A]] | ||
* [[ | * [[Orexin B]] | ||
* [[Insomnia]] | |||
* [[Narcolepsy]] | |||
* [[G protein-coupled receptor]] | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Neuroscience]] | [[Category:Neuroscience]] | ||
Latest revision as of 03:38, 13 February 2025
TCS-OX2-29[edit]
TCS-OX2-29 is a selective antagonist of the orexin receptor OX2, which is involved in the regulation of wakefulness and sleep. Orexin receptors are a type of G protein-coupled receptor that bind the neuropeptides orexin A and orexin B. These receptors play a crucial role in maintaining arousal, appetite, and energy homeostasis.
Mechanism of Action[edit]
TCS-OX2-29 functions by selectively inhibiting the OX2 receptor, thereby blocking the action of orexin peptides at this receptor site. This inhibition can lead to a decrease in arousal and an increase in sleep, making it a potential therapeutic agent for conditions such as insomnia and narcolepsy.
Pharmacological Effects[edit]
The primary effect of TCS-OX2-29 is the modulation of sleep-wake cycles. By antagonizing the OX2 receptor, TCS-OX2-29 can promote sleep and reduce wakefulness. This effect is particularly useful in studying the role of orexin in sleep disorders and in developing treatments for such conditions.
Research and Development[edit]
Research on TCS-OX2-29 has focused on its potential applications in treating sleep disorders. Studies have shown that blocking the OX2 receptor can lead to increased sleep duration and improved sleep quality. This makes TCS-OX2-29 a valuable tool in both basic research and clinical applications.
